Heart drugs tested to stop AFib after TAVR
NCT ID NCT07519161
First seen Jun 25, 2026 · Last updated Jun 27, 2026 · Updated 1 time
Summary
This trial tests whether two heart medications, metoprolol and amiodarone, can prevent new-onset atrial fibrillation (AFib) in people who develop minor rhythm issues after transcatheter aortic valve replacement (TAVR). About 198 participants will be randomly assigned to one of the drugs or to observation only. The study will track who develops AFib over 90 days and monitor for side effects.
What this could mean
Our plain-language read of the trial. This is informational only — not medical advice or a prediction.
- Active substance
- Metoprolol succinate and amiodarone
- What this could lead to
- If successful, this could provide a clear drug strategy to prevent atrial fibrillation after TAVR, reducing stroke and hospitalization risk.
- What could go wrong
- This is a relatively small, early-stage trial (198 people) with no phase designation. Both drugs have known side effects, and the results may not apply to all patients.
This is an AI summary of the original study and may miss details. Read our disclaimer.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for ATRIAL FIBRILLATION are added.
By submitting, you agree to our Terms of use
Conditions
The condition(s) this trial relates to.
As listed by the trial registrant
The condition terms exactly as the trial's registrant entered them.
More trials for these conditions
Other studies related to the condition(s) this trial covers.
- A tiny neck implant could catch Stroke-Causing clots before they reach the brain
- Could a new injection tame atrial fibrillation?
- Which blood thinner is safer for heart patients? a Head-to-Head test
- Can a cholesterol drug keep atrial fibrillation at bay after ablation?
- Can a One-Two punch fix a leaky heart valve and restore normal rhythm?
- Could a guided Self-Care plan tame atrial Fibrillation's return?